Introduction
============

Ranking fifth most common malignancies, hepatocellular carcinoma (HCC) is diagnosed in \>500,000 individuals worldwide (2011) ([@b1-ol-0-0-9523]). With an increasing incidence, HCC has become the third most common cause of cancer-associated mortality worldwide (2010) ([@b2-ol-0-0-9523]). The majority of patients with HCC exhibit aggressive symptoms upon diagnosis and the median 1-year survival rate is \<30% ([@b3-ol-0-0-9523],[@b4-ol-0-0-9523]). Traditionally, HCC is detected using biomarkers, including α-fetoprotein ([@b5-ol-0-0-9523],[@b6-ol-0-0-9523]), with 39--65% sensitivity and 76--94% specificity ([@b7-ol-0-0-9523]). Several biomarkers, such as miR-101-1, miR-221, miR-638 can be used as diagnostic and prognostic indicators of HCC ([@b8-ol-0-0-9523]--[@b10-ol-0-0-9523]). However, there are still a number of biomarkers that may be biologically relevant for the development of HCC. Therefore, a more efficient biomarker with improved accuracy is urgently required.

MicroRNAs (miRNAs) are small non-coding RNA molecules with an approximate length of 23 nucleotides. miRNAs serve as post-transcriptional regulators of gene expression by binding to the 3′-untranslated region of mRNA ([@b11-ol-0-0-9523],[@b12-ol-0-0-9523]). Previous studies have demonstrated that the dysregulation of specific miRNAs contributes to the progression of hepatocarcinogenesis ([@b13-ol-0-0-9523],[@b14-ol-0-0-9523]). Therefore, these molecules may represent promising biomarkers for the diagnosis of HCC. A previous study demonstrated that miRNA (miR)-122-5p was downregulated in patients with HCC ([@b15-ol-0-0-9523]); however, its molecular mechanism and diagnostic significance remain to be elucidated.

The Cancer Genome Atlas (TCGA; <http://cancergenome.nih.gov/>) is a program, which contains RNA sequencing (RNA-Seq) data on 32 types of tumor without limitations or restrictions by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). The Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) is an online public resource provided by the National Center for Biotechnology Information (NCBI) in 2000. The GEO covers ample gene chip expression data, as well as data from non-chip technologies, such as serial analysis of gene and mass spectrometry. GEO provides large quantities of high-throughput data and is one of the most comprehensive public gene expression data resources available currently.

Therefore, the present study examined the accuracy of miR-122-5p in distinguishing HCC patients from healthy controls based on data collected from TCGA and GEO. The association between distinct clinicopathological features and the expression of miR-122-5p was also investigated. To further clarify the regulatory mechanism of miR-122-5p in HCC, subsequent bioinformatic analyses were conducted. The present study aims to perform a quantitative evaluation of the association between miR-122-5p in HCC and pathophysiological processes, specifically investigating the type of genes and signaling pathways that are associated with downregulated miR-122-5p levels in HCC specimens.

Materials and methods
=====================

### Collection of TCGA and GEO data

TCGA provided miRNA raw sequencing data from 370 HCC cases and 50 adjacent liver tissue samples. The publicly available RNA-Seq data were downloaded directly from the TCGA launch data portal via bulk download of the liver hepatocellular carcinoma (LIHC), RNASeqV2 (data type) and level 3 (data level) cancer tissues collected on January 1, 2017 ([@b16-ol-0-0-9523]). Additionally, the GEO database was searched and GEO datasets (GSE6857, GSE12717, GSE10694, GSE21279, GSE22058, GSE21362, GSE20971, GSE39678, GSE31383, GSE40744, GSE50013, GSE36915, GSE54751, GSE57555, GSE67882, GSE74618, GSE65708 and GSE64989) ([@b17-ol-0-0-9523]) containing an expression profile or fold-change value of miR-122-5p in HCC and control samples were included. There was no restriction on the specific type of non-cancerous control. Cell line assays or assays without the expression value were excluded. The following information obtained from Genomic Spatial Event (GSE) (<https://www.ncbi.nlm.nih.gov/geo/>) ([@b18-ol-0-0-9523]) chips was recorded: Main contributor (the name that ranked first), publishing year, country, sample type, experiment type, the platform of the GSE chips, and the number of patients with HCC and controls. All expression values for miR-122-5p in GEO were log2 scaled. The number, mean and standard deviation for the control and experimental groups were calculated based on each single gene chip.

### Literature search

Pertinent studies were retrieved in PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>), Wiley online library (<http://onlinelibrary.wiley.com/>), Sciencedirect (<http://www.sciencedirect.com/>), Web of science (<http://login.webofknowledge.com/>), Cochrane Central Register of Controlled Trials (<http://www.cochranelibrary.com/>), EMSCO (<http://emsco.com/>), China National Knowledge Infrastructure (CNKI) (<http://www.cnki.net/>), China Biology Medicine disc (<http://www.sinomed.ac.cn/>), Chongqing VIP (<http://www.cqvip.com/>) and Wan Fang Data (<http://www.wanfangdata.com.cn/>) using the following key terms: (malignant\* OR cancer OR tumor OR tumor OR neoplasm\* OR carcinoma) AND (hepatocellular OR liver OR hepatic OR HCC) AND (miR-122 OR miRNA-122 OR microRNA-122 OR miR122 OR miRNA122 OR microRNA122 OR 'miR 122' OR 'miRNA 122' OR 'microRNA 122' OR miR-122-5p OR miRNA-122-5p OR microRNA-122-5p). Studies that did not provide true positive (TP), false positive (FP), true negative (TN) and false negative (FN) results were excluded. The author, publishing year, sample type, number of HCC patients and controls, and the number of TP, FP, TN and FN results were recorded as basic information.

### Selection of prospective target genes of miR-122-5p

The potential target mRNAs of miR-122-5p were predicted based on 12 online prediction databases, including miRWalk, TargetScan and miRMap ([@b19-ol-0-0-9523]). Genes recorded in \>5 of the 12 prediction databases were selected ([@b20-ol-0-0-9523]). The selected predicted target genes were further intersected with TCGA and GEO differentially expressed genes. The overlapping genes were considered as potential target genes of miR-122-5p.

### Bioinformatic analyses using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and annotation and the protein-protein interaction (PPI) network

Using the Database for Annotation, Visualization and Integrated Discovery (DAVID; [david.abcc.ncifcrf.gov](david.abcc.ncifcrf.gov)), GO annotation was subsequently conducted based on the prospective target mRNAs. A total of three GO terms, including biological process, cellular component and molecular function, were used to identify the enrichment of target genes. KEGG pathway analysis ([www.genome.jp/kegg](www.genome.jp/kegg)) was applied to identify noteworthy pathways associated with the selected target genes. The Bingo plug-in component from Cytoscape 3.4.0 ([www.cytoscape.org](www.cytoscape.org)) and GraphPad Prism 7 software (GraphPad Software, Inc., La Jolla, CA, USA) were employed to visualize the network of GO terms and KEGG pathways, respectively ([@b21-ol-0-0-9523]). GO, KEGG and Protein Analysis Through Evolutionary Relationships (PANTHER) pathway analyses were implemented in DAVID to summarize the essential functions of potential target genes of miR-122-5p ([@b22-ol-0-0-9523]). To explicitly determine the interactions and connections between hub genes, the PPI network was applied using Search Tool for the Retrieval of Interacting Genes/Proteins ([www.string-db.org](www.string-db.org)) ([@b23-ol-0-0-9523]). The nodes and edges presented the genes and reciprocal actions between genes, whose number would reveal the dominant hub genes of miR-122-5p in HCC. P\<0.05 was considered to indicate a statistically significant difference.

### Statistical analysis

Student\'s t-test for independent samples and one way analysis of variance (with Bonferroni\'s post-hoc test) was performed using SPSS 19 software (IBM Corp., Armonk, NY, USA) to determine the association between the miR-122-5p expression profile and various clinicopathological parameters. P\<0.05 was considered to indicate a statistically significant difference.

SPSS 19 software was applied to generate a receiver operator characteristic (ROC) curve to assess diagnostic efficacy. The relative expression level of miR-122-5p from the microarray included in the GEO was processed separately. All samples were pooled with HCC and controls to conduct another diagnostic trial. Meta-DiSc 1.4 (<http://www.hrc.es/investigacion/metadisc_en.htm>) was used to generate combined effect and forest plots using a random effects model. The sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic score (DS) and diagnostic odds ratio (DOR) were recorded. The area under the curve (AUC) and point where sensitivity and specificity are equal (index Q\*) were calculated. Threshold and meta-regression analyses were conducted to determine heterogeneity in the present study, and P\<0.1 or I^2^\>50% were considered to represent marked heterogeneity.

The analysis was repeated as aforementioned, and the threshold and meta-regression analyses were performed in Stata14 (StataCorp LLC, College Station, TX, USA). Deek\'s funnel plot and Fagan plot analyses were performed to examine publication bias and to detect the diagnostic value of miR-122-5p in HCC.

Results
=======

### miR-122-5p expression levels and associated clinicopathological features in TCGA and GEO datasets

The average expression level of miR-122-5p in the TCGA cohort was decreased in the patients with HCC compared with the controls (P\<0.001; [Fig. 1A](#f1-ol-0-0-9523){ref-type="fig"}). There were 375 patients with HCC and 50 controls in the TCGA cohort, and 955 patients with HCC and 685 controls in the GEO cohort. From the expression data in 20 GSE chips, all the clinicopathological features mentioned in chips were gathered and associations with miR-122-5p expression levels were investigated. The downregulation of miR-122-5p was associated with HCC tissues (P\<0.001; [Fig. 1B](#f1-ol-0-0-9523){ref-type="fig"}), tumor vascular invasion (P\<0.001), metastasis (P=0.001), tissue (compared with serum) (P\<0.001), virus infection state (P=0.001) and sex (P=0.006) in the GEO cohort ([Table I](#tI-ol-0-0-9523){ref-type="table"}).

### Diagnostic value based on data from TCGA and GEO

The relative expression level of miR-122-5p data collected from TCGA demonstrated 81.07% sensitivity and 84.00% specificity. The area under the ROC curve (AUC) was 0.865 \[95% confidence interval (CI), 0.829--0.896; [Fig. 1C](#f1-ol-0-0-9523){ref-type="fig"}\]. In the GEO cohort, the overall SEN and the SPE were 66.77 and 79.70%, respectively, with an AUC of 0.749 (95% CI, 0.726--0.771; [Fig. 1D](#f1-ol-0-0-9523){ref-type="fig"}). The diagnostic value of every individual chip was also calculated ([Table II](#tII-ol-0-0-9523){ref-type="table"}) ([@b15-ol-0-0-9523],[@b24-ol-0-0-9523]--[@b40-ol-0-0-9523]).

### Meta-analysis based on the previous literature

In total, 6,854 studies were collected from the literature. Following exclusion of repeated and irrelevant articles, 53 full texts were read. Finally, 4 studies were included ([Table III](#tIII-ol-0-0-9523){ref-type="table"}; [Fig. 2](#f2-ol-0-0-9523){ref-type="fig"}) ([@b41-ol-0-0-9523]--[@b44-ol-0-0-9523]). In the meta-analysis, the pooled SEN, SPE, PLR, NLR, DOR and AUC values were 0.73 (95% CI, 0.56--0.86), 0.79 (95% CI, 0.69--0.86), 3.43 (95% CI, 2.38--4.95), 0.34 (95% CI, 0.20--0.59), 10.11 (95% CI, 4.70--21.77) and 0.83 (95% CI, 0.79--0.86), respectively, when Stata14 was applied ([Fig. 3](#f3-ol-0-0-9523){ref-type="fig"}). No significant publication bias was observed in the meta-analysis using Deek\'s funnel plot (P=0.10; [Fig. 4](#f4-ol-0-0-9523){ref-type="fig"}). The pre-test probability value of miR-122-5p in patients with HCC was 20%, and the post-test probability values, considering PLR and NLR results, were 46 and 8%, respectively, based on Fagan\'s nomogram ([Fig. 5](#f5-ol-0-0-9523){ref-type="fig"}). The results were also calculated using Meta-DiSc 1.4 (data not shown).

### Overall assessment of diagnostic value

The data from GEO, TCGA and eligible studies were combined in order to perform a pooled diagnostics test. In Stata14, the pooled SEN, SPE, PLR, NLR and DOR values were 0.60 (95% CI, 0.48--0.71), 0.81 (95% CI, 0.70--0.89), 3.20 (95% CI, 1.93--5.30), 0.49 (95% CI, 0.37--0.65) and 6.49 (95% CI, 3.23--13.08). The AUC value was 0.76 (95% CI, 0.72--0.80; [Fig. 6](#f6-ol-0-0-9523){ref-type="fig"}). No significant publication bias was observed in the meta-analysis using Deek\'s funnel plot (P=0.96; [Fig. 7](#f7-ol-0-0-9523){ref-type="fig"}). The pre-test probability value for miR-122-5p expression in patients with HCC was 63%, and the post-test probability values, considering PLR and NLR results, were 84 and 45%, respectively, based on Fagan\'s nomogram ([Fig. 8](#f8-ol-0-0-9523){ref-type="fig"}). In Meta-DiSc1.4, the pooled SEN, SPE, PLR, NLR and DOR values were also calculated by Meta-DiSc 1.4 (data not shown).

### Identification of potential target mRNAs of miR-122-5p

A total of 61,399 target genes were predicted by 12 online software programs, and 5,657 genes that were detected ≥5 times were regarded as potential target genes of miR-122-5p. Additionally, differentially expressed genes assembled from the TCGA and GEO databases were integrated to generate the intersection of the two databases. The 5,657 potential target genes intersected 198 genes, with 3,278 differentially expressed genes from the TCGA database and 5,122 differentially expressed genes from the GEO database. These overlapping genes were used in subsequent bioinformatic analyses.

### Bioinformatic analyses of the potential target genes of miR-122-5p

Further investigations were conducted to determine the functional mechanism of miR-122-5p in the progression of HCC. For the results of GO pathway analysis in DAVID, the potential targets of miR-122-5p were notably associated with the regulation of cell proliferation for cell adhesion (P=1.22×10^−4^), proteinaceous extracellular matrix (P=1.20×10^−4^) and extracellular matrix structural constituent (P=5.57×10^−3^; [Table IV](#tIV-ol-0-0-9523){ref-type="table"}; [Fig. 9](#f9-ol-0-0-9523){ref-type="fig"}). Furthermore, KEGG pathway analysis identified biosynthesis of amino acids, carbon metabolism, biosynthesis of antibiotics, arginine and proline metabolism, arginine biosynthesis, Chagas disease (American trypanosomiasis), amoebiasis, glycolysis/gluconeogenesis, the pentose phosphate pathway and toxoplasmosis as significant (P\<0.05). In addition, the most enriched term in the PANTHER analysis was salvage pathways of pyrimidine deoxyribonucleotides ([Table V](#tV-ol-0-0-9523){ref-type="table"}; [Fig. 10](#f10-ol-0-0-9523){ref-type="fig"}). In the PPI analysis, the network demonstrated 198 nodes and 57 edges ([Fig. 11A](#f11-ol-0-0-9523){ref-type="fig"}). Genes with a combined score \>0.900, based on available experimental data and importing known protein complexes from curated databases ([@b23-ol-0-0-9523]), including minichromosome maintenance complex component (MCM)4, MCM8, MCM10, chromatin licensing and DNA replication factor 1, cell division cycle (CDC) 6, CDC25A and checkpoint kinase 1, were defined as hub genes. CDC6, MCM4 and MCM8, with 24, 24 and 22 interactions with other hub genes in the network, respectively, were recognized as hub genes of the highest significance ([Fig. 11B](#f11-ol-0-0-9523){ref-type="fig"}).

Discussion
==========

A number of studies have confirmed that the downregulation of miR-122-5p in HCC was associated with metastasis and a poor prognosis ([@b45-ol-0-0-9523],[@b46-ol-0-0-9523]). Therefore, the present study further investigated these conclusions. The expression of miR-122-5p was decreased in patients with HCC compared with that in controls in the TCGA and GEO databases. Additionally, decreased miR-122-5p expression was significantly associated with metastasis and vascular invasion in the GEO dataset, suggesting that the downregulation of miR-122-5p may lead to a poor prognosis, and that miR-122-5p may act as a tumor suppressor in HCC. Furthermore, miR-122-5p expression varied in different virus infection states, indicating that miR-122-5p may be associated with virus-associated HCC. In tissues, miR-122-5p expression was decreased compared with that in serum. However, reflecting the limited number of serum samples, further studies are required to confirm distinctions in the diagnostic accuracy between tissues and serum.

With regards to diagnostic value, the pooled AUC was 0.76 (95% CI, 0.72--0.80), suggesting that miR-122-5p possessed a moderate degree of accuracy in diagnostic tests and that it may be a promising biomarker for the diagnosis of patients with HCC. A discrepancy in sample type and patients may reflect the observed differences in the AUC among TCGA, GEO and meta-analysis studies. Li *et al* ([@b47-ol-0-0-9523]), He *et al* ([@b48-ol-0-0-9523]) and Huang *et al* ([@b49-ol-0-0-9523]) conducted integrated research to examine the diagnostic value of miR-122-5p, and the AUC values were 0.81, 0.78 and 0.77, respectively, consistent with the results of the present study. In search strategy, Wu *et al* ([@b46-ol-0-0-9523]) applied 2 public databases: PubMed and Embase, Qi *et al* ([@b44-ol-0-0-9523]) applied Medline and CancerLit Embase prior to July 31, 2015. Huang *et al* ([@b49-ol-0-0-9523]) analyzed the diagnostic value of miRNAs in patients with HCC utilizing the Medline, Embase and CNKI databases. The present study aimed to explore the potential clinical value of miR-122-5p in HCC. In addition to pertinent literature regarding miR-122-5p, data from TCGA and GEO public databases were also extracted. The SEN, SPE, PLR, NLR, DS and DOR values were determined in Meta-DiSc 1.4. The aforementioned study was repeated, excluding threshold analysis and meta-regression in Stata14. Deek\'s funnel plot and Fagan plot were displayed to test the publication bias and to detect the diagnostic value of miR-122-5p in HCC. The heterogeneity in the meta-analysis of these studies did not reflect a threshold effect or clinical features. Subgroup and meta-regression analyses were not performed, reflecting the limited number of studies collected. The source of heterogeneity in the pooled meta-analysis was not determined by meta-regression.

In the PPI network, CDC6, MCM4 and MCM8 were highlighted as the most significant hub genes with multiple interactions in the network. Further examination of these notable genes would reveal the function for miR-122-5p in HCC. CDC6 is a necessary regulator of DNA replication and is inextricably associated with tumorigenesis ([@b50-ol-0-0-9523]). High CDC6 expression has been associated with various types of cancer. In ovarian cancer, Deng *et al* ([@b51-ol-0-0-9523]) discovered that the elevated expression of CDC6 may accelerate cell proliferation and worsen prognosis. In addition, CDC6 may participate in chemotherapy resistance in bladder cancer ([@b52-ol-0-0-9523]). Previous studies have also demonstrated oncogenetic functions for CDC6 in HCC ([@b53-ol-0-0-9523],[@b54-ol-0-0-9523]). Xiong *et al* ([@b55-ol-0-0-9523]) demonstrated that CDC6 overexpression may increase susceptibility to HCC, and the Cdc6-515A\>G polymorphism may attenuate CDC6 expression to decrease the risk of carcinogenesis. Therefore, studies focused on approaches to downregulate CDC6 have been reported. HKH40A was utilized to disrupt the cell cycle and to promote apoptosis, during which CDC6 was downregulated ([@b56-ol-0-0-9523]). MCM4 is also an essential replication modulator. In cervical cancer ([@b57-ol-0-0-9523]), non-small cell lung cancer ([@b58-ol-0-0-9523]) and laryngeal squamous cell carcinoma ([@b59-ol-0-0-9523]), the upregulation of MCM4 was also observed. Studach *et al* ([@b60-ol-0-0-9523]) observed upregulation of MCM4 in HCC in X/c-myc bitransgenics, indicating the identical expression profile of MCM4 in HCC. However, the MCM4 polymorphism may generate contradictory results. For example, Nan *et al* ([@b61-ol-0-0-9523]) reported that MCM4 may decrease the risk of HCC. Another notable hub gene of miR-122-5p, MCM8, which is also a gene replication regulator, may modulate DNA replication through interactions with other MCM proteins, including the aforementioned MCM4 ([@b62-ol-0-0-9523]). MCM8 was overexpressed in chronic myelogenous leukemia ([@b63-ol-0-0-9523]) and the overexpression of MCM8 was associated with the poor prognosis in pancreatic cancer ([@b64-ol-0-0-9523]). However, to the best of our knowledge, there are no available studies regarding the function of MCM8 in HCC. As the hub genes of miR-122-5p with the most interactions with other hub genes, CDC6, MCM4 and MCM8 all exerted the function of genome replication. Consistently, regulation of cell proliferation for cell adhesion was also highlighted in the GO analysis. Therefore, we hypothesized that miR-122-5p may be involved in the biological process of gene replication. Considering that miR-122-5p exhibited significantly decreased expression in HCC, whereas CDC6 and MCM4 were upregulated, miR-122-5p may represent a therapeutic target and biomarker for HCC.

In conclusion, the downregulation of miR-122-5p in HCC demonstrated diagnostic value worthy of further attention. Furthermore, this molecule may function as a tumor suppressor by modulating genome replication. Additional experiments and studies are required to verify this discovery.
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![Diagnostic value of miR-122-5p expression in HCC. (A) Scatter chart of groups in TCGA database. (B) ROC curve demonstrating the diagnostic value of miR-122-5p expression based on TCGA database. (C) Scatter chart of groups in the GEO database. (D) ROC curves of miR-122-5p for the diagnosis of HCC based on the GEO database. \*\*\*P\<0.001. miR, microRNA; HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; ROC, receiver operating characteristic; AUC, area under the curve.](ol-16-06-6918-g00){#f1-ol-0-0-9523}

![Flow chart of the study selection in the meta-analysis. TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus.](ol-16-06-6918-g01){#f2-ol-0-0-9523}

![The SROC curve analysis for miR-122-5p in the 4 included studies by Stata14. SROC curves summarize the overall diagnostic accuracy. SROC, summary receiver operating characteristic; SENS, sensitivity; SPEC, specificity; AUC, area under the curve.](ol-16-06-6918-g02){#f3-ol-0-0-9523}

![Deek\'s funnel plot evaluating the publication bias based on the included studies in Stata14. P=0.10, no significant publication bias was observed in the meta-analysis. ESS, effective sample size.](ol-16-06-6918-g03){#f4-ol-0-0-9523}

![Fagan\'s nomogram detecting the clinical use of miR-122-5p in the qualified studies in HCC based on Stata14. The pre-test probability value of miR-122-5p in HCC was 20%, and the post-test probability values, considering the LR_positive and LR_negative results, were 46 and 8%, respectively. miR, microRNA; HCC, hepatocellular carcinoma; LR_positive, positive likelihood ratio; LR_negative, negative likelihood ratio; post_prob_pos, post-test positive probability; post_prob_neg, post-test negative probability.](ol-16-06-6918-g04){#f5-ol-0-0-9523}

![The SROC curve analysis for miR-122-5p based on The Cancer Genome Atlas, Gene Expression Omnibus and eligible studies in Stata14. SROC curves summarize the overall diagnostic accuracy. SROC, summary receiver operating characteristic; SENS, sensitivity; SPEC, specificity; AUC, area under the curve.](ol-16-06-6918-g05){#f6-ol-0-0-9523}

![Deek\'s funnel plot examining the publication bias based on The Cancer Genome Atlas, Gene Expression Omnibus and eligible studies in Stata14. No significant publication bias was observed in the meta-analysis; P=0.96. ESS, effective sample size.](ol-16-06-6918-g06){#f7-ol-0-0-9523}

![The Fagan plot was displayed to test the diagnostic value of miR-122-5p based on The Cancer Genome Atlas, Gene Expression Omnibus and eligible studies in HCC by Stata14. The pre-test probability value of miR-122-5p in HCC was 63%, and the post-test probability values, considering the LR_positive and LR_negative results, were 84 and 45%, respectively. miR, microRNA; HCC, hepatocellular carcinoma; LR_positive, positive likelihood ratio; LR_negative, negative likelihood ratio; post_prob_pos, post-test positive probability; post_prob_neg, post-test negative probability.](ol-16-06-6918-g07){#f8-ol-0-0-9523}

![GO functional annotation according to the putative target genes of miR-122-5p in HCC. The top 10 terms with highest significance in every section of the GO analysis are presented respectively with the number of enriched target genes. GO, gene ontology; miR, microRNA; HCC, hepatocellular carcinoma.](ol-16-06-6918-g08){#f9-ol-0-0-9523}

![KEGG and PANTHER pathway enrichment analysis of miR-122-5p target genes. The number of genes is indicated in the figure. KEGG, Kyoto Encyclopedia of Genes and Genomes; PANTHER, Protein Analysis Through Evolutionary Relationships; miR, microRNA.](ol-16-06-6918-g09){#f10-ol-0-0-9523}

![The PPI network of potential target genes of miR-122-5p in HCC. (A) The network comprising 198 potential target genes of miR-122-5p. The PPI enrichment P-value was 1.13×10^−11^ for the network containing 198 nodes and 57 edges. The disconnected nodes are not presented. (B) The 7 hub genes with the most interaction lines in the PPI analysis. PPI, protein-protein interaction; miR, microRNA; HCC, hepatocellular carcinoma.](ol-16-06-6918-g10){#f11-ol-0-0-9523}

###### 

Association between the expression of miR-122-5p and clinicopathological parameters in HCC based on the Gene Expression Omnibus database.

                                    miR-122-5p relevant expression   
  ------------------------- ------- -------------------------------- ---------
  Tissue                                                             
    Non-cancerous           685     15.35±1.40                       \<0.001
    HCC                     955     14.18±1.58                       
  Age, years                                                         
    \<50                    145     15.40±1.60                       0.894
    ≥50                     117     15.38±1.09                       
  Sex                                                                
    Male                    453     15.24±1.54                       0.006
    Female                  105     14.78±1.39                       
  Clinical TNM stage                                                 
    Early stage             82      15.25±0.53                       0.979
    Advanced stage          66      15.25±0.44                       
  Metastasis                                                         
    −                       466     15.36±0.80                       0.001
    +                       171     15.09±0.99                       
  Tumor vascular invasion                                            
    −                       91      14.13±0.38                       \<0.001
    +                       81      12.81±1.09                       
  Alcohol abuse                                                      
    −                       120     15.26±0.48                       0.860
    +                       36      15.25±0.49                       
  Virus infection state                                              
    −                       51      14.55±1.64                       0.001
    HBV                     175     15.47±1.87                       
    HCV                     55      14.82±1.13                       
  Cirrhosis                                                          
    −                       80      15.11±0.82                       0.178
    +                       97      14.98±1.07                       
  Chemotherapy                                                       
    −                       4       12.35±0.41                       0.599
    +                       42      12.01±1.25                       
  Sample                                                             
    Tissue                  1,626   14.56±1.51                       \<0.001
    Serum                   14      20.10±2.55                       

HCC, hepatocellular carcinoma; SD, standard deviation; miR, microRNA; TNM, Tumor-Node-Metastasis; HBV, hepatitis B virus; HCV, hepatitis C virus.

###### 

Summary of every individual GEO chip of miR-122-5p in HCC.

  Accession no.   Country       Sample type   Experiment type                                          Platform   HCC/Control   TP    FP   FN    TN    (Refs.)
  --------------- ------------- ------------- -------------------------------------------------------- ---------- ------------- ----- ---- ----- ----- ----------------------
  GSE6857         USA           Tissue        Non-coding RNA profiling by array                        GPL4700    241/241       115   41   126   200   ([@b24-ol-0-0-9523])
  GSE12717        China         Tissue        Non-coding RNA profiling by array                        GPL7274    10/6          3     0    7     6     ([@b25-ol-0-0-9523])
  GSE10694        China         Tissue        Non-coding RNA profiling by array                        GPL6542    78/88         57    39   21    49    ([@b26-ol-0-0-9523])
  GSE21279        China         Tissue        Non-coding RNA profiling by high throughput sequencing   GPL9052    4/11          1     7    3     4     ([@b27-ol-0-0-9523])
  GSE22058        USA           Tissue        Expression profiling by array                            GPL6793    96/96         61    13   35    83    ([@b15-ol-0-0-9523])
  GSE21362        Japan         Tissue        Non-coding RNA profiling by array                        GPL10312   73/73         12    7    61    66    ([@b28-ol-0-0-9523])
  GSE20971        France        Tissue        Non-coding RNA profiling by array                        GPL10231   49/9          33    1    16    8     ([@b29-ol-0-0-9523])
  GSE39678        South Korea   Tissue        Non-coding RNA profiling by array                        GPL15852   16/8          2     6    14    2     ([@b30-ol-0-0-9523])
  GSE31383        USA           Tissue        Non-coding RNA profiling by array                        GPL10122   9/10          2     0    7     10    ([@b31-ol-0-0-9523])
  GSE40744        USA           Tissue        Non-coding RNA profiling by array                        GPL14613   39/37         12    0    27    37    ([@b32-ol-0-0-9523])
  GSE50013        USA           Plasma        Expression profiling by RT-PCR                           GPL15497   10/4          4     4    6     0     ([@b33-ol-0-0-9523])
  GSE36915        Taiwan        Tissue        Non-coding RNA profiling by array                        GPL8179    68/21         57    13   11    8     ([@b34-ol-0-0-9523])
  GSE54751        USA           Tissue        Expression profiling by RT-PCR                           GPL18262   10/10         8     2    2     8     ([@b35-ol-0-0-9523])
  GSE57555        Japan         Tissue        Non-coding RNA profiling by array                        GPL18044   5/16          5     8    0     8     ([@b36-ol-0-0-9523])
  GSE67882        India         Tissue        Non-coding RNA profiling by array                        GPL10850   4/8           4     1    0     7     ([@b37-ol-0-0-9523])
  GSE74618        Spain         Tissue        Non-coding RNA profiling by array                        GPL14613   218/20        80    1    138   19    ([@b38-ol-0-0-9523])
  GSE65708        China         Tissue        Other                                                    GPL16850   6/8           5     0    1     8     ([@b39-ol-0-0-9523])
  GSE64989        Germany       Tissue        Non-coding RNA profiling by array                        GPL16384   8/10          6     5    2     5     ([@b40-ol-0-0-9523])

miR, microRNA; HCC, hepatocellular carcinoma; TP, true positive; FP, false positive; TN, true negative; FN, false negative.

###### 

Basic information of included studies in this meta-analysis.

  Country   Age, mean ± SD (HCC/Control)   Sex, female/male   Sample type   Experiment type   Cut-off value   nHCC/Control   TP   FP   FN   TN   QUADAS   (Refs.)
  --------- ------------------------------ ------------------ ------------- ----------------- --------------- -------------- ---- ---- ---- ---- -------- ----------------------
  China     Not shown                      9/36               Serum         RT-PCR            2.6963          45/50          40   11   5    39   5        ([@b41-ol-0-0-9523])
  China     53.57±11.59/40.20±6.61         49/176             Serum         RT-qPCR           NR              135/90         65   12   70   78   8        ([@b42-ol-0-0-9523])
  China     Not shown                      44/146             Serum         RT-qPCR           0.7             101/89         71   28   30   61   9        ([@b43-ol-0-0-9523])
  China     Not shown                      Not shown          Serum         RT-qPCR           0.475           48/24          39   4    9    20   8        ([@b44-ol-0-0-9523])

HCC, hepatocellular carcinoma; TP, true positive; FP, false positive; TN, true negative; FN, false negative; QUADAS, quality assessment tool for diagnostic accuracy studies; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; SD, standard deviation.

###### 

The top 10 most enriched terms in every GO section, based on the target genes of miR-122-5p in hepatocellular carcinoma.

  Category    Term                                                                 Count   P-value
  ----------- -------------------------------------------------------------------- ------- -------------
  GOTERM_BP   GO:0007155\~cell adhesion                                            16      1.22×10^−4^
  GOTERM_BP   GO:0044344\~cellular response to fibroblast growth factor stimulus   5       2.76×10^−4^
  GOTERM_BP   GO:0051289\~protein homotetramerization                              6       4.42×10^−4^
  GOTERM_BP   GO:0000086\~G2/M transition of mitotic cell cycle                    7       3.51×10^−3^
  GOTERM_BP   GO:0000082\~G1/S transition of mitotic cell cycle                    6       4.71×10^−3^
  GOTERM_BP   GO:0006260\~DNA replication                                          7       6.38×10^−3^
  GOTERM_BP   GO:0071260\~cellular response to mechanical stimulus                 5       6.96×10^−3^
  GOTERM_BP   GO:0050729\~positive regulation of inflammatory response             5       7.67×10^−3^
  GOTERM_BP   GO:0006941\~striated muscle contraction                              3       8.16×10^−3^
  GOTERM_BP   GO:0006094\~gluconeogenesis                                          4       1.14×10^−2^
  GOTERM_CC   GO:0005578\~proteinaceous extracellular matrix                       12      1.20×10^−4^
  GOTERM_CC   GO:0009897\~external side of plasma membrane                         9       1.80×10^−3^
  GOTERM_CC   GO:0005615\~extracellular space                                      26      3.52×10^−3^
  GOTERM_CC   GO:0031012\~extracellular matrix                                     10      3.98×10^−3^
  GOTERM_CC   GO:0000775\~chromosome, centromeric region                           4       2.16×10^−2^
  GOTERM_CC   GO:0009986\~cell surface                                             12      2.70×10^−2^
  GOTERM_CC   GO:0010008\~endosome membrane                                        6       4.47×10^−2^
  GOTERM_CC   GO:0042383\~sarcolemma                                               4       5.92×10^−2^
  GOTERM_CC   GO:0005829\~cytosol                                                  44      6.95×10^−2^
  GOTERM_CC   GO:0043209\~myelin sheath                                            5       7.45×10^−2^
  GOTERM_MF   GO:0005201\~extracellular matrix structural constituent              5       5.57×10^−3^
  GOTERM_MF   GO:0043225\~anion transmembrane-transporting ATPase activity         3       5.77×10^−3^
  GOTERM_MF   GO:0016301\~kinase activity                                          8       1.45×10^−2^
  GOTERM_MF   GO:0031683\~G-protein beta/gamma-subunit complex binding             3       1.87×10^−2^
  GOTERM_MF   GO:0042803\~protein homodimerization activity                        15      2.36×10^−2^
  GOTERM_MF   GO:0005518\~collagen binding                                         4       2.58×10^−2^
  GOTERM_MF   GO:0050840\~extracellular matrix binding                             3       3.08×10^−2^
  GOTERM_MF   GO:0031821\~G-protein coupled serotonin receptor binding             2       4.17×10^−2^
  GOTERM_MF   GO:0005509\~calcium ion binding                                      14      4.20×10^−2^
  GOTERM_MF   GO:0005524\~ATP binding                                              24      4.48×10^−2^

GO, Gene Ontology; miR, microRNA; BP, biological process; CC, cellular component; MF, molecular function.

###### 

KEGG and PANTHER Pathway analysis of potential target genes of miR-122-5p.

  Category          Term                                                 Count   P-value
  ----------------- ---------------------------------------------------- ------- -------------
  KEGG_PATHWAY      hsa01230:Biosynthesis of amino acids                 6       1.67×10^−3^
  KEGG_PATHWAY      hsa01200:Carbon metabolism                           7       2.00×10^−3^
  KEGG_PATHWAY      hsa01130:Biosynthesis of antibiotics                 8       1.18×10^−2^
  KEGG_PATHWAY      hsa00330:Arginine and proline metabolism             4       2.05×10^−2^
  KEGG_PATHWAY      hsa00220:Arginine biosynthesis                       3       2.25×10^−2^
  KEGG_PATHWAY      hsa05142:Chagas disease (American trypanosomiasis)   5       3.33×10^−2^
  KEGG_PATHWAY      hsa05146:Amoebiasis                                  5       3.54×10^−2^
  KEGG_PATHWAY      hsa00010:Glycolysis/Gluconeogenesis                  4       4.35×10^−2^
  KEGG_PATHWAY      hsa00030:Pentose phosphate pathway                   3       4.49×10^−2^
  KEGG_PATHWAY      hsa05145:Toxoplasmosis                               5       4.93×10^−2^
  PANTHER_PATHWAY   P02774:Salvage pyrimidine deoxyribonucleotides       2       5.89×10^−2^

KEGG, Kyoto Encyclopedia of Genes and Genomes; PANTHER, Protein Analysis Through Evolutionary Relationships; miR, microRNA.
